Cargando…
Human Neural Stem Cell-Based Drug Product: Clinical and Nonclinical Characterization
Translation of cell therapies into clinical practice requires the adoption of robust production protocols in order to optimize and standardize the manufacture and cryopreservation of cells, in compliance with good manufacturing practice regulations. Between 2012 and 2020, we conducted two phase I cl...
Autores principales: | Profico, Daniela Celeste, Gelati, Maurizio, Ferrari, Daniela, Sgaravizzi, Giada, Ricciolini, Claudia, Projetti Pensi, Massimo, Muzi, Gianmarco, Cajola, Laura, Copetti, Massimiliano, Ciusani, Emilio, Pugliese, Raffaele, Gelain, Fabrizio, Vescovi, Angelo Luigi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653902/ https://www.ncbi.nlm.nih.gov/pubmed/36362211 http://dx.doi.org/10.3390/ijms232113425 |
Ejemplares similares
-
Human neural stem cell transplantation in ALS: initial results from a phase I trial
por: Mazzini, Letizia, et al.
Publicado: (2015) -
Human neural stem cells drug product: Microsatellite instability analysis
por: Grespi, Valentina, et al.
Publicado: (2022) -
Transplantation of clinical-grade human neural stem cells reduces neuroinflammation, prolongs survival and delays disease progression in the SOD1 rats
por: Zalfa, Cristina, et al.
Publicado: (2019) -
Establishment of stable iPS-derived human neural stem cell lines suitable for cell therapies
por: Rosati, Jessica, et al.
Publicado: (2018) -
Results from Phase I Clinical Trial with Intraspinal Injection of Neural Stem Cells in Amyotrophic Lateral Sclerosis: A Long‐Term Outcome
por: Mazzini, Letizia, et al.
Publicado: (2019)